150 related articles for article (PubMed ID: 38000116)
21. Carcinoembryonic antigen, α-fetoprotein, and Ki67 as biomarkers and prognostic factors in intrahepatic cholangiocarcinoma: A retrospective cohort study.
Qiang Z; Zhang W; Jin S; Dai K; He Y; Tao L; Yu H
Ann Hepatol; 2021; 20():100242. PubMed ID: 32841741
[TBL] [Abstract][Full Text] [Related]
22. Comparison of combined hepatocellular and cholangiocarcinoma with hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Lee WS; Lee KW; Heo JS; Kim SJ; Choi SH; Kim YI; Joh JW
Surg Today; 2006; 36(10):892-7. PubMed ID: 16998683
[TBL] [Abstract][Full Text] [Related]
23. Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging.
Lin G; Toh CH; Wu RC; Ko SF; Ng SH; Chou WC; Tseng JH
Int J Clin Pract; 2008 Aug; 62(8):1199-205. PubMed ID: 17537192
[TBL] [Abstract][Full Text] [Related]
24. Radiofrequency ablation versus liver resection and liver transplantation for small combined hepatocellular-cholangiocarcinoma stratified by tumor size.
Peng S; Dong SC; Bai DS; Zhang C; Jin SJ; Jiang GQ
Langenbecks Arch Surg; 2023 Mar; 408(1):119. PubMed ID: 36918430
[TBL] [Abstract][Full Text] [Related]
25. Imaging features of combined hepatocellular and cholangiocarcinoma compared with those of hepatocellular carcinoma and intrahepatic cholangiocellular carcinoma in a Chinese population.
Wang Y; Yang Q; Li S; Luo R; Mao S; Shen J
Clin Radiol; 2019 May; 74(5):407.e1-407.e10. PubMed ID: 30799097
[TBL] [Abstract][Full Text] [Related]
26. Clinical features and outcomes of combined hepatocellular carcinoma and cholangiocarcinoma versus hepatocellular carcinoma versus cholangiocarcinoma after surgical resection: a propensity score matching analysis.
Lin CW; Wu TC; Lin HY; Hung CM; Hsieh PM; Yeh JH; Hsiao P; Huang YL; Li YC; Wang YC; Shu CW; Chen YS
BMC Gastroenterol; 2021 Jan; 21(1):20. PubMed ID: 33413162
[TBL] [Abstract][Full Text] [Related]
27. Patients' prognosis of intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma after resection.
Song P; Midorikawa Y; Nakayama H; Higaki T; Moriguchi M; Aramaki O; Yamazaki S; Aoki M; Teramoto K; Takayama T
Cancer Med; 2019 Oct; 8(13):5862-5871. PubMed ID: 31407490
[TBL] [Abstract][Full Text] [Related]
28. Comparing the clinicopathological characteristics of combined hepatocellular-cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification.
Yen CC; Yen CJ; Shan YS; Lin YJ; Liu IT; Huang HY; Yeh MM; Chan SH; Tsai HW
Histopathology; 2021 Oct; 79(4):556-572. PubMed ID: 33837585
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathological factors impact the survival outcome following the resection of combined hepatocellular carcinoma and cholangiocarcinoma.
Yap AQ; Chen CL; Yong CC; Kuo FY; Wang SH; Lin CC; Liu YW; Lin TL; Li WF; Millan CA; Wang CC
Surg Oncol; 2013 Mar; 22(1):55-60. PubMed ID: 23102615
[TBL] [Abstract][Full Text] [Related]
30. Role of autophagy-related protein in the prognosis of combined hepatocellular carcinoma and cholangiocarcinoma after surgical resection.
Perng DS; Hung CM; Lin HY; Morgan P; Hsu YC; Wu TC; Hsieh PM; Yeh JH; Hsiao P; Lee CY; Li YC; Wang YC; Chen YS; Lin CW
BMC Cancer; 2021 Jul; 21(1):828. PubMed ID: 34273969
[TBL] [Abstract][Full Text] [Related]
31. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.
Lee JH; Chung GE; Yu SJ; Hwang SY; Kim JS; Kim HY; Yoon JH; Lee HS; Yi NJ; Suh KS; Lee KU; Jang JJ; Kim YJ
J Clin Gastroenterol; 2011 Jan; 45(1):69-75. PubMed ID: 20142755
[TBL] [Abstract][Full Text] [Related]
32. Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors.
Wang Y; Zhu GQ; Zhou CW; Li N; Yang C; Zeng MS
Eur Radiol; 2022 Aug; 32(8):5166-5178. PubMed ID: 35316365
[TBL] [Abstract][Full Text] [Related]
33. Clinicopathological analysis of 14 patients with combined hepatocellular carcinoma and cholangiocarcinoma.
Yu XH; Xu LB; Zeng H; Zhang R; Wang J; Liu C
Hepatobiliary Pancreat Dis Int; 2011 Dec; 10(6):620-5. PubMed ID: 22146626
[TBL] [Abstract][Full Text] [Related]
34. Prognosis of hepatocellular carcinoma expressing cytokeratin 19: comparison with other liver cancers.
Lee JI; Lee JW; Kim JM; Kim JK; Chung HJ; Kim YS
World J Gastroenterol; 2012 Sep; 18(34):4751-7. PubMed ID: 23002345
[TBL] [Abstract][Full Text] [Related]
35. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection.
Na SK; Choi GH; Lee HC; Shin YM; An J; Lee D; Shim JH; Kim KM; Lim YS; Chung YH; Lee YS
PLoS One; 2018; 13(6):e0198138. PubMed ID: 29879137
[TBL] [Abstract][Full Text] [Related]
36. The effect of trans arterial chemoembolization in the management of intrahepatic cholangiocarcinoma. A systematic review and meta-analysis.
Lv TR; Hu HJ; Liu F; Regmi P; Jin YW; Li FY
Eur J Surg Oncol; 2022 May; 48(5):956-966. PubMed ID: 35065841
[TBL] [Abstract][Full Text] [Related]
37. Factors affecting overall survival and disease-free survival after surgery for hepatocellular carcinoma: a nomogram-based prognostic model-a Western European multicenter study.
Masuda Y; Yeo MHX; Burdio F; Sanchez-Velazquez P; Perez-Xaus M; Pelegrina A; Koh YX; Di Martino M; Goh BKP; Tan EK; Teo JY; Romano F; Famularo S; Ferrari C; Griseri G; Piardi T; Sommacale D; Gianotti L; Molfino S; Baiocchi G; Ielpo B
Updates Surg; 2024 Jan; 76(1):57-69. PubMed ID: 37839048
[TBL] [Abstract][Full Text] [Related]
38. Response evaluation of locoregional therapies in combined hepatocellular-cholangiocarcinoma and intrahepatic cholangiocarcinoma versus hepatocellular carcinoma: a propensity score matched study.
Mukund A; V Srinivasan S; Rana S; Vijayaraghavan R; Patidar Y; Arora V; Jindal A; Choudhury A; Shasthry SM; Sarin SK
Clin Radiol; 2022 Feb; 77(2):121-129. PubMed ID: 34789395
[TBL] [Abstract][Full Text] [Related]
39. Influence of surgical margin width on survival rate after resection of intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.
Jiang JH; Fang DZ; Hu YT
BMJ Open; 2023 May; 13(5):e067222. PubMed ID: 37156579
[TBL] [Abstract][Full Text] [Related]
40. The significance of the predominant component in combined hepatocellular-cholangiocarcinoma: MRI manifestation and prognostic value.
Sheng R; Yang C; Zhang Y; Wang H; Zheng B; Han J; Sun W; Zeng M
Radiol Med; 2023 Sep; 128(9):1047-1060. PubMed ID: 37474663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
